Filings & corporate actions
80 results filed
CSVNext results · Q2 FY27
Expected 27 Oct 2026 – 10 Nov 2026
Estimate: filed 27–41 days after quarter end, last 5 times
Dividend
₹48.00 per share · last 22 Apr 2026
2026
- 4 AugresultsResults · Q1 FY27 · standalone-1.9%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026-0.7%NSE
- 28 AprresultsResults · Q4 FY26 · standalone-1.0%NSE
- 22 AprdividendDividend · ₹48.00 per share-2.3%
- 17 AprshareholdingShareholding · 31 Mar 20260.0%NSE
- 25 FebresultsResults · Q3 FY26 · standalone-2.9%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-0.6%NSE
Reaction to results · all yearsrose on day 0 in 31 of 79 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 4 Aug 2026 | -1.9% | -4.4% | -7.0% | 1.1× |
| Q4 FY26 | 28 Apr 2026 | -1.0% | -2.3% | -10.7% | 0.9× |
| Q3 FY26 | 25 Feb 2026 | -2.9% | -8.5% | -22.4% | 10.8× |
| Q2 FY26 | 29 Oct 2025 | +1.7% | -1.9% | -7.2% | 1.6× |
| Q1 FY26 | 31 Jul 2025 | -4.7% | -10.7% | -12.2% | 2.6× |
| Q4 FY25 | 14 May 2025 | +4.4% | +3.6% | +2.1% | 3.1× |
| Q3 FY25 | 27 Feb 2025 | +0.5% | +9.9% | +17.2% | 30.3× |
| Q2 FY25 | 7 Nov 2024 | -1.6% | -5.9% | -4.8% | 0.4× |
| Q1 FY25 | 26 Jul 2024 | -1.6% | -4.0% | +1.9% | 4.8× |
| Q4 FY24 | 13 May 2024 | 0.0% | +11.8% | +25.7% | 2.7× |
| Q3 FY24 | 23 Feb 2024 | -1.0% | -4.5% | -15.6% | 2.5× |
| Q2 FY24 | 8 Nov 2023 | +0.2% | -0.9% | +4.5% | 0.4× |
| Q1 FY24 | 11 Aug 2023 | -2.7% | -1.7% | -3.0% | 3.3× |
| Q4 FY23 | 11 May 2023 | +8.9% | +12.2% | +23.5% | 12.5× |
| Q3 FY23 | 24 Feb 2023 | +5.4% | +2.9% | +1.2% | 10.2× |
| Q2 FY23 | 10 Nov 2022 | -0.9% | -1.4% | +4.8% | 0.9× |
| Q1 FY23 | 27 Jul 2022 | -0.3% | +3.7% | -3.2% | 1.5× |
| Q4 FY22 | 27 Apr 2022 | -0.7% | -1.2% | -7.2% | 0.3× |
| Q3 FY22 | 24 Feb 2022 | +0.6% | -2.1% | +4.5% | 2.4× |
| Q2 FY22 | 27 Oct 2021 | +2.5% | -0.6% | +2.1% | 1.3× |
| Q1 FY22 | 28 Jul 2021 | +1.6% | +7.9% | +9.0% | 11.0× |
| Q4 FY21 | 6 May 2021 | +0.6% | +0.2% | +0.3% | 1.5× |
| Q3 FY21 | 24 Feb 2021 | -0.1% | +2.0% | -3.8% | 1.1× |
| Q2 FY21 | 28 Oct 2020 | -1.6% | -1.1% | -1.6% | 0.8× |
| Q1 FY21 | 29 Jul 2020 | +3.9% | +9.2% | +14.5% | 3.2× |
| Q4 FY20 | 20 May 2020 | +1.1% | +2.9% | +6.4% | 0.9× |
| Q3 FY20 | 26 Feb 2020 | +1.4% | +5.9% | -12.9% | 9.4× |
| Q2 FY20 | 13 Nov 2019 | -1.1% | +5.1% | +5.1% | 1.1× |
| Q1 FY20 | 30 Jul 2019 | -1.7% | -1.8% | -2.7% | 10.9× |
| Q4 FY19 | 9 May 2019 | -1.6% | -2.2% | -1.5% | 0.7× |
| Q3 FY19 | 6 Mar 2019 | -1.4% | -1.2% | +1.2% | 2.1× |
| Q2 FY19 | 21 Nov 2018 | -1.0% | +1.5% | 0.0% | 0.4× |
| Q1 FY19 | 7 Aug 2018 | 0.0% | +2.9% | +7.1% | 0.5× |
| Q4 FY18 | 13 Jun 2018 | -2.2% | -0.2% | +4.9% | 0.3× |
| Q3 FY18 | 26 Feb 2018 | +1.1% | +2.7% | +5.5% | 0.1× |
| Q2 FY18 | 2 Nov 2017 | +4.3% | -1.2% | -1.4% | 2.1× |
| Q1 FY18 | 26 Jul 2017 | -0.1% | -1.5% | -5.9% | 0.3× |
| Q4 FY17 | 11 May 2017 | -0.7% | -1.9% | -4.4% | 0.5× |
| Q3 FY17 | 28 Feb 2017 | -0.9% | +3.3% | +14.4% | 3.7× |
| Q2 FY17 | 9 Nov 2016 | +2.0% | +0.6% | +3.9% | 1.1× |
| Q1 FY17 | 28 Jul 2016 | -0.2% | -2.1% | -5.8% | 5.8× |
| Q4 FY16 | 29 Apr 2016 | -0.2% | -0.1% | -3.1% | 0.3× |
| Q3 FY16 | 5 Feb 2016 | +1.7% | -0.1% | +5.8% | 1.0× |
| Q2 FY16 | 14 Jan 2016 | +0.6% | -2.3% | -1.6% | 0.6× |
| Q1 FY16 | 27 Jul 2015 | -0.2% | +7.6% | +4.7% | 4.6× |
| Q4 FY15 | 20 May 2015 | +0.9% | +6.8% | +6.3% | 2.1× |
| Q3 FY15 | 24 Feb 2015 | -2.6% | -0.1% | -3.0% | 0.9× |
| Q2 FY15 | 18 Nov 2014 | +0.5% | +6.8% | -0.4% | 0.4× |
| Q1 FY15 | 31 Jul 2014 | -1.7% | +5.5% | +0.4% | 0.2× |
| Q4 FY14 | 5 May 2014 | -1.0% | +2.0% | +16.6% | 2.4× |
| Q3 FY14 | 3 Mar 2014 | +0.7% | +0.3% | +12.0% | 0.7× |
| Q2 FY14 | 15 Nov 2013 | -1.6% | +1.5% | +5.4% | 0.1× |
| Q1 FY14 | 3 Aug 2013 | -0.4% | +2.7% | -3.8% | 0.1× |
| Q4 FY13 | 8 May 2013 | +1.0% | +0.3% | +4.1% | 0.2× |
| Q3 FY13 | 26 Feb 2013 | -0.8% | +0.4% | +7.9% | 2.9× |
| Q2 FY13 | 31 Oct 2012 | +0.1% | +0.5% | -0.3% | 0.4× |
| Q1 FY13 | 26 Jul 2012 | +0.9% | +0.1% | -3.7% | 0.3× |
| Q4 FY12 | 4 May 2012 | +0.2% | -2.1% | -2.1% | 0.3× |
| Q3 FY12 | 23 Feb 2012 | -1.3% | -4.2% | -6.3% | 0.6× |
| Q2 FY12 | 16 Nov 2011 | -0.6% | -4.9% | -4.6% | 0.2× |
| Q1 FY12 | 28 Jul 2011 | +0.9% | -2.1% | +3.0% | 0.1× |
| Q4 FY11 | 26 Apr 2011 | +3.4% | +3.7% | +0.8% | 11.0× |
| Q3 FY11 | 16 Feb 2011 | +3.1% | +2.9% | +3.4% | 9.5× |
| Q2 FY11 | 25 Oct 2010 | -0.3% | +0.5% | +3.2% | 0.2× |
| Q1 FY11 | 19 Jul 2010 | -0.2% | -3.7% | -7.2% | 1.4× |
| Q4 FY10 | 27 Apr 2010 | -0.4% | +2.3% | +0.4% | 0.2× |
| Q3 FY10 | 24 Feb 2010 | -1.3% | +0.7% | +9.2% | 15.5× |
| Q2 FY10 | 27 Oct 2009 | +1.0% | +1.8% | +2.0% | 0.6× |
| Q1 FY10 | 22 Jul 2009 | +1.2% | +9.7% | +15.3% | 1.8× |
| Q4 FY09 | 28 Apr 2009 | -0.2% | +6.1% | +17.9% | 0.1× |
| Q3 FY09 | 17 Feb 2009 | -0.9% | -1.2% | -1.2% | 54.3× |
| Q2 FY09 | 23 Oct 2008 | -5.8% | -0.2% | +9.1% | 0.2× |
| Q1 FY09 | 24 Jul 2008 | +0.5% | +0.2% | +6.4% | 9.8× |
| Q4 FY08 | 23 Apr 2008 | -2.2% | -3.4% | -9.5% | 0.4× |
| Q3 FY08 | 21 Feb 2008 | -1.2% | +0.6% | -18.1% | 0.4× |
| Q2 FY08 | 30 Oct 2007 | -2.1% | -3.2% | -5.9% | 12.5× |
| Q1 FY08 | 17 Jul 2007 | -2.7% | -6.9% | -8.7% | 0.3× |
| Q4 FY07 | 17 Apr 2007 | -2.1% | +3.0% | +3.9% | 1.4× |
| Q3 FY07 | 26 Mar 2007 | -3.1% | -0.2% | +2.6% | 1.8× |
| Average | -0.1% | +0.7% | +1.1% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q3 FY25
CSVRevenue YoY+7.7%
Profit YoY+20.1%
Interest cost YoY+6.7%
Revenue QoQ-7.3%
Profit QoQ-18.6%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | -16.7% | -13.7% | -10.8% | -9.2% | -8.6% | -6.7% |
| Profit | -21.8% | -17.4% | -24.2% | -11.0% | -5.2% | -2.6% |
Key data
CSVOpen3,020.10
Day range3,004.00 – 3,057.80
52-week range3,001.10 – 4,898.00
From 52w high-37.8%
RSI (14)39.2
ATR (14)61.95
Volume16.5K
Avg volume (20D)18.6K
Rel volume0.89×
Volatility (1Y)19.0%
Turnover₹5.0Cr
SMA 50 / 2003,198.96 / 3,516.42
Delivery percentage
Latest · 6 Oct 202651.9%
20-day avg54.1%
1-year avg56.6%
Percentile (own history)24th
Range10.2–100.0%
Sessions1,731
Over the last 20 sessions SANOFI settled 54.1% of its traded quantity, which is above average for an NSE equity. Its one-year average is 56.6%, so recent sessions are running 2.5 points lower than usual. The latest session ranks higher than 24% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.75% | -1.82% | -4.51% | -11.98% | -6.68% | -35.83% |
Valuation
CSVMarket cap₹7,017 Cr
P/E (TTM)21.7
EPS (TTM)140.60
Shares outstanding2.30Cr
Listed19 May 2003
Ownership
CSVPromoter60.40%
Promoter Δ QoQ0.00 pp
Public39.60%
FII5.69%
DII19.87%
Pledged0.00%
Quarterly results · consolidated
CSV| Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 732.4 | 463.5 | 524.0 | 514.9 |
| YoY chg | — | -34.4% | -26.7% | -25.8% |
| Net profit (₹ Cr) | 136.6 | 103.2 | 82.2 | 91.3 |
| YoY chg | — | -16.0% | -45.9% | -33.7% |
| Net margin | 18.7% | 22.3% | 15.7% | 17.7% |
| EPS | 59.31 | 44.81 | 35.69 | 39.60 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 60.40% · public 39.60%2021-092026-06
- Promoter
- Public and others
- Promoter
- 60.40%
- Public
- 39.60%
- Promoter change
- 0.00 pp
- Filed
- 20 Jul 2026
- FII
- 5.69%
- DII
- 19.87%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Trend | |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 706.1 | 714.6 | 693.9 | 732.4 | 463.5 | 524.0 | 514.9 | |
| Other income | 15.7 | 11.8 | 12.0 | 6.5 | 4.8 | 2.3 | 5.9 | |
| Total income | 721.8 | 726.4 | 705.9 | 738.9 | 468.3 | 526.3 | 520.8 | |
| Total expenses | 538.4 | 516.5 | 517.1 | 523.8 | 357.2 | 413.7 | 406.6 | |
| └ Finance costs | 0.7 | 0.3 | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 | |
| └ Depreciation | 9.8 | 9.9 | 10.2 | 10.0 | 9.0 | 9.0 | 9.6 | |
| Profit before tax | 183.4 | 209.9 | 188.8 | 188.4 | 92.1 | 112.6 | 122.2 | |
| Tax expense | 60.5 | 57.9 | 51.1 | 51.8 | 23.9 | 30.4 | 30.9 | |
| Net profit | 122.9 | 151.9 | 137.7 | 136.6 | 103.2 | 82.2 | 91.3 | |
| EPS | 53.37 | 65.95 | 59.79 | 59.31 | 44.81 | 35.69 | 39.64 | |
| Net margin | 17.41% | 21.26% | 19.84% | 18.65% | 22.27% | 15.69% | 17.73% | |
| PBT margin | 25.97% | 29.37% | 27.21% | 25.72% | 19.87% | 21.49% | 23.73% | |
| Tax rate | 32.99% | 27.60% | 27.07% | 27.49% | 25.95% | 27.00% | 25.29% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 28 Feb 2025.
SANOFI at a glance
- SANOFI closed at ₹3,047 on 6 Oct 2026, +0.75% on the day, -35.8% over one year, 37.8% below its 52-week high of ₹4,898.
- Delivery was 51.9% of traded quantity on 6 Oct 2026, the 24th percentile of its own 1,731 sessions with a reading (20-session average 54.1%, 1-year average 56.6%).
- Market capitalisation is ₹7,017 crore at a trailing P/E of 21.7 (trailing EPS ₹140.6).
- Q3 FY25 results (consolidated, filed 27 Feb 2025): revenue ₹515 crore (-25.8% year on year), net profit ₹91 crore (-33.7%); the price moved +0.5% on the first session after.
- Promoters held 60.40% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 27 Oct 2026 and 10 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE058A01010
SeriesEQ
Listed19 May 2003
History from19 May 2003
Sessions5,806
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE